Separate indirect from direct design evidence (SIDDE)

Fixed effects model: 

               comparison k  nma direct indir. RoR z p-value
 daridorexant:eszopiclone 0 0.94      .   0.94   . .       .
 daridorexant:lemborexant 0 0.99      .   0.99   . .       .
   daridorexant:melatonin 0 0.75      .   0.75   . .       .
     daridorexant:placebo 1 0.99   0.99      .   . .       .
  daridorexant:suvorexant 0 0.76      .   0.76   . .       .
  eszopiclone:lemborexant 0 1.05      .   1.05   . .       .
    eszopiclone:melatonin 0 0.80      .   0.80   . .       .
      eszopiclone:placebo 3 1.06   1.06      .   . .       .
   eszopiclone:suvorexant 0 0.82      .   0.82   . .       .
    lemborexant:melatonin 0 0.76      .   0.76   . .       .
      lemborexant:placebo 1 1.01   1.01      .   . .       .
   lemborexant:suvorexant 0 0.78      .   0.78   . .       .
        melatonin:placebo 1 1.33   1.33      .   . .       .
     melatonin:suvorexant 0 1.03      .   1.03   . .       .
       suvorexant:placebo 2 1.30   1.30      .   . .       .

Legend:
 comparison - Treatment comparison
 k          - Number of studies providing direct evidence
 nma        - Estimated treatment effect (OR) in network meta-analysis
 direct     - Estimated treatment effect (OR) derived from direct evidence
 indir.     - Estimated treatment effect (OR) derived from indirect evidence
 RoR        - Ratio of Ratios (direct versus indirect)
 z          - z-value of test for disagreement (direct versus indirect)
 p-value    - p-value of test for disagreement (direct versus indirect)
[1] "Percent of comparisons where there is some evidence (p-value<0.05) of disagreement between direct and indirect sources: NaN. (0 out of 0 comparisons)."
[1] "File created on 2022-06-09"
